Research Progress on Targeted Degradation of Transcription Factors Based on PROTAC Technology
Abstract
For transcription factors (TFs), biological importance has not always translated into pharmacological tractability. These proteins coordinate gene expression programs involved in proliferation, differentiation, immune homeostasis, and development, yet many disease-relevant TFs lack the compact binding pockets that make enzymes or receptors easier to target. Their extended protein-DNA and protein-protein interfaces, together with frequent intrinsic disorder, further complicate ligand discovery. PROTAC technology offers a different route: instead of requiring continuous functional blockade, a degrader recruits an E3 ubiquitin ligase to the TF and lowers the cellular amount of the target through ubiquitin-proteasome-dependent degradation. In this review, TF-directed degraders are considered according to how the target is recognized. Four representative modes are discussed: ligand-binding-domain-directed PROTACs for nuclear receptors, small-molecule degraders that use noncanonical binding surfaces, nucleic-acid-recognition-element-mediated degraders, and biological PROTACs (bioPROTACs). Examples centered on ERα, AR, STAT3, and c-Myc are used to compare where each approach works well and where it remains limited. Particular attention is paid to the scarcity of selective binders, the narrow E3-ligase repertoire currently used, ternary-complex geometry, intracellular and nuclear delivery, and the distinct developability problems of different degrader formats. The review also considers how broader E3-ligase recruitment, structure-guided optimization, improved delivery, and AI-assisted discovery may extend targeted degradation to TFs that remain difficult to modulate by conventional pharmacology.